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ABSTRACT: Nonsteroidal anti-inflammatory drugs
have been associated with hepatotoxicity in suscepti-
ble patients. One such example is nimesulide, a prefer-
ential cyclooxygenase 2–inhibitor, widely used for the
treatment of inflammation and pain. It was suggested
that nimesulide could exert its hepatotoxicity by alter-
ing hepaticmitochondrial function,whichwas demon-
strated in vitro. The objective of this studywas to verify
whether liver mitochondria isolated from rats treated
with doses of nimesulidewell above therapeutic levels
possessed decreased calcium tolerance and oxidative
phosphorylation, which indicates in vivo nimesulide
mitochondrial toxicity. Male and female rats received
nimesulide or its vehicle twice daily, for 5 days, and
were killed on the seventh day for the isolation of
liver mitochondria. Mitochondrial respiration, trans-
membrane electric potential, and calcium tolerance
were characterized in all experimental groups. Nime-
sulide had no effect on liver mitochondrial function.
Indexes of mitochondrial integrity, calcium loading ca-
pacity, and oxidative phosphorylation efficiency were
unchanged between liver mitochondria from treated
and control animals. In the animals tested, no evi-
dence ofdegradedmitochondrial functiondue tonime-
sulide administration could be found. The results cor-
roborate the notion that despite recognized in vitro
mitochondrial toxicity, nimesulide does not cause de-
tectablemitochondrial dysfunction inWistar rats, even
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when administered in much higher concentrations
than those known to have anti-inflammatory effects.
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INTRODUCTION
Nimesulide (N-[4-nitro-2-phenoxyphenyl]-methane-
sulfonamide) is a widely used nonsteroidal anti-
inflammatory drug (NSAID) that, similarly to other
NSAIDs, has been associated with rare, but sometimes
severe, hepatic adverse reactions. The relevant fre-
quency of adverse reactions is comparable with that of
other NSAIDs, which are known to be associated with
hepatotoxicity [1,2]. The hepatic events reported dur-
ing treatment with nimesulide include asymptomatic
and reversible elevation of liver enzymes [1,3–5], acute
hepatitis associated with hepatocellular necrosis [6],
cholestasis [7], and some isolated cases of fatal acute
hepatic failure [8,9].
So far, the molecular mechanisms underlying the
hepatotoxicity of nimesulide have not been fully
elucidated. Nimesulide is extensively metabolized
in the liver, predominantly to the metabolite 4-
hydroxy-nimesulide [10]. Nimesulide-induced hepato-
cellular damage usually presents with necrosis in the
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centrilobular region, where cytochrome P450 activity
is highest [11]. Genetic predisposition could favor the
production of uncommon metabolites that can either
exert a toxic effect directly or induce an immunologi-
cal reaction by forming adducts with the cytochrome
P450 complex, which are subsequently internalized by
B lymphocytes [12]. As opposed to what has been de-
scribed, studies on the viability and growth of the hu-
manhepatoma cell lineHepG2 showed that nimesulide
or its metabolites exhibited no appreciable cytotoxic
activity [13].
Mitochondria are a potential target of drug toxic-
ity. In fact, it is well known that a large number of nat-
ural, commercial, pharmaceutical, and environmental
chemicals manifest their toxicity by interfering with
mitochondrial bioenergetics [14,15]. Several in vitro
studies suggest that one of the reasons for the hep-
atic toxicity of nimesulide may be the impairment of
liver mitochondrial function. Previous in vitro studies
carried out on isolated mitochondria and isolated hep-
atocytes have shown variousmitochondrial effects. For
example, nimesulide uncouples mitochondria through
a protonophoretic mechanism and decreases the phos-
phorylation index (ADP/O ratio) and the respiratory
control ratio (RCR) [16–20].
Probably one of the most relevant aspects of
nimesulide-induced hepatotoxicity is the ability of the
drug to induce mitochondrial permeability transition
(MPT). In fact, Mingatto et al. [18] demonstrated that
nimesulide acts as a potent protonophoretic uncoupler
and NAD(P)H oxidant on isolated rat liver mitochon-
dria, inducing calcium efflux through MPT induction.
MPT is a phenomenon related to the formation and
opening of protein pores (the MPT pores) in the inner
mitochondrial membrane [21]. MPT can be caused by
excessive mitochondrial calcium accumulation and ox-
idative stress generation [22], leading ultimately to cell
death [23], which could be an important contribution
for the pathophysiology of nimesulide-induced hepa-
totoxicity. A temporal relation between mitochondrial
depolarization, generation of superoxide radical, and
induction of theMPT by nimesulidewas established by
Tay et al. [24]. According to these authors, mitochon-
drial uncoupling induced by nimesulide is the trigger
for induction of the MPT, which further leads to the
generation of oxidative stress.
Despite extensive knowledge of the effects of
nimesulide on isolated liver mitochondria, data are
lacking regarding hepatic mitochondrial function of
nimesulide-treated rats, namely and most importantly,
the susceptibility of liver mitochondria from treated
animals to undergo MPT. The objective of the present
study was to verify if nimesulide administration to
Wistar rats could induce early mitochondrial alter-
ations comparable to those observed in in vitro studies.
In agreement with previous in vitro work, the initial
hypothesis was that liver mitochondria isolated from
nimesulide-treated rats showed decreased tolerance
to calcium (enhanced MPT) and altered respiratory
parameters.
MATERIALS AND METHODS
Chemicals
Nimesulide was provided by Helsinn Health-
care SA (and dissolved in absolute DMSO).
Bovine serum albumin (BSA), rotenone, N-(2-
hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)
(HEPES), cyclosporin A, and ethylene glycol-bis(β-
aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA)
were purchased from Sigma Chemical Co. (St. Louis,
MO). Tetraphenylphosphonium (TPP+) and sucrose
were from Merck (Darmstadt, Germany). All other
reagents and chemicals were commercial products
of the highest purity grade available. Solutions were
prepared in deionized ultra-pure water.
Animals
Wistar rats (250–300 g) were used for the exper-
iments and kept under controlled light (12 h/12 h
day/night cycle), temperature (22–24◦C), and humid-
ity (50%–60%) conditions, andwith free access to water
(pH 5.5) and food. The experiments reported here were
carried out in accordance with the National Require-
ments for Vertebrate Animal Research and in accor-
dancewith the EuropeanConvention for the Protection
of Animals Used for Experimental and Other Scientific
Purposes. Twelve animals were randomly divided into
four groups (each n= 3) of six male and six female
Wistar rats as follows: (i) control male animals (n= 3)
receiving DMSO (vehicle) twice daily (injected i.p.) for
5 days and killed on the seventh day for isolating liver
mitochondria; (ii) treated male rats (n= 3) receiving
i.p. injections of nimesulide 50 mg/kg twice daily for
5 days and killed on the seventh day for isolating liver
mitochondria; (iii) control female animals (n= 3) re-
ceiving DMSO (vehicle) twice daily (injected i.p.) for
5 days and killed on the seventh day for isolating liver
mitochondria; (iv) treated female rats (n= 3) receiving
i.p. injections (total volume of administration: 0.1 mL)
of nimesulide 50 mg/kg twice daily for 5 days and
killed on the seventh day for isolating liver mitochon-
dria. In the same day of experiments, one treated and
one control animal of the same gender were used. The
nimesulide dosage used in the present study is much
higher than those known to have anti-inflammatory ac-
tion inman as the objectivewas to verify potential toxic
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effects on mitochondrial function. The usual human
therapeutic regimen is 100 mg nimesulide taken twice
daily for 5 days [25]. In the present study, we used the
same length of time and a dosage that is about 30 times
higher than the maximum recommended dose admin-
istered to a 70-kg human.
Isolation of Rat Liver Mitochondria
Rat liver mitochondria were isolated by conven-
tional differential centrifugation [26] from the livers of
overnight-fasted rats, with slight modifications. Rats
were killed by decapitation, and their livers were har-
vested and rinsed with an ice-cold buffer containing
250mMsucrose, 10mMHEPES, 1mMEGTA, and 0.1%
defatted BSA. The pH was adjusted to 7.4 with KOH.
Livers were trimmed and homogenized for 1 min with
a motor-driven Teflon Potter homogenizer in the pres-
ence of ice-cold buffer (7 g/50 mL). Liver homogenate
was centrifuged at 800 × g for 10 min (Sorvall RC-5C,
Plus, SS 34 rotor, 4◦C) and its supernatant at 10,000 × g
for 10 min. The mitochondrial pellet was resuspended
using a paintbrush and centrifuged twice at 10,000 × g
for 10 min to obtain a final mitochondrial suspension.
EGTA and defatted BSA were omitted from the final
washing medium, which was adjusted to pH 7.2. Mito-
chondrial proteinwasdeterminedby the biuretmethod
usingBSAas a standard. Themitochondrial suspension
(≈30–40mgprotein/mL)was kept on ice during exper-
iments, which were carried out after a 20-min recovery
and within 5 h.
Mitochondrial Oxygen Consumption
Measurements
Oxygen consumptionwasmeasured using aClark-
type oxygen electrode (Yellow Springs Instruments,
OH) connected to a recorder (Kipp & Zonen, BD 112)
in a thermostated water-jacketed sealed glass cham-
ber with constant magnetic stirring, at 25◦C. Reac-
tions were conducted in 1 mL of medium containing
125 mM sucrose, 65 mM KCl, 2.5 mM MgCl2, 5 mM
KH2PO4, 5 mM HEPES (pH 7.2), supplemented with
3 µM rotenone. The reactions were initiated by adding
potassium succinate to a final concentration of 5 mM.
State 2 respiration was monitored for at least 2 min
prior to adding ADP (0.1 mM) to initiate state 3 respi-
ration. State 4 respiration followed exhaustion of ADP.
RCRs and ADP/O ratios were determined according
to Estabrook [27]. The scale of oxygen uptake was cali-
brated according to the oxygen consumed by submito-
chondrial particles after addition of titrated solutions of
NADH.
Measurements of Mitochondrial
Transmembrane Electrical Potential
The mitochondrial membrane potential () was
monitored indirectly based on the activity of the
lipophilic cation tetraphenylphosphonium (TPP+) us-
ing a TPP+-selective electrode prepared in our labo-
ratory, in combination with a Ag/AgCl-saturated ref-
erence electrode (Tacussel, Model MI 402) [28]. Both
the TPP+ electrode and the reference electrode were in-
serted into an open vessel with magnetic stirring and
connected to a pH meter (Jenway, Model 3305). The
signals were fed to a potentiometric recorder (Kipp &
Zonen, Model BD 121). Mitochondria were incubated
in the reaction medium consisting of 125 mM sucrose,
65 mM KCl, 2.5 mM MgCl2, 5 mM KH2PO4, 5 mM
HEPES (pH 7.2), supplemented with 3 µM rotenone,
containing 3 µM TPP+. The reaction was stirred con-
tinuously and the temperaturemaintained at 25◦C. The
experiments were started by adding 5 mM succinate to
mitochondria in suspension at 1 mg protein/mL. ADP
or Ca2+ was added and  fluctuations recorded after
a steady-state distribution of TPP+ had been reached
(around 2 min of recording). The experiments with
Ca2+ were carried out in a medium consisting of 0.2 M
sucrose, 10 mM Tris–MOPS (pH 7.4), 1 mM KH2PO4,
and 10 µM EGTA, supplemented with 2 µM rotenone.
The  was estimated as indicated by Kamo et al.
[27] from the following equation (at 25◦C):  = 59 ×
log (v/V) – 59 × log (10 E/59 – 1), where v, V, and
E stand for mitochondrial volume, volume of the in-
cubation medium, and deflection of the electrode po-
tential from the baseline, respectively. Amatrix volume
of 1.1 µL per mg protein was assumed. No correction
was made for the “passive” binding of TPP+ to the
mitochondrial membranes, since the purpose of the ex-
periments was to show relative changes in potentials
rather than absolute values. As a consequence, a slight
overestimation of the  values is anticipated.
Measurement of Mitochondrial Swelling
Changes in the mitochondrial osmotic volume
were followed by monitoring the decrease in ab-
sorbance (light scattering) at 540 nm with a Jasco V-560
spectrophotometer as previously described [26]. The
reactions were performed with 1 mg mitochondrial
protein in 2 mL of a medium consisting of 0.2 M su-
crose, 10 mM Tris–MOPS (pH 7.4), 1 mM KH2PO4, and
10 µM EGTA, supplemented with 2 µM rotenone. The
reaction was stirred continuously and the temperature
was maintained at 25◦C. Mitochondria were energized
with 5 mM succinate for 2 min before adding 60 nmol
CaCl2. CyclosporinA (1µM, in ethanol) was added just
before adding succinate.
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Mitochondrial Ca2+ Fluxes
Mitochondrial Ca2+ fluxesweremeasured bymon-
itoring the changes in Ca2+ concentration in the
reaction medium using a Ca2+-selective electrode ac-
cording to previously described procedures [29]. The
reactions were conducted in an open vessel with mag-
netic stirring in 1mL of the reactionmedium composed
of 0.2 M sucrose, 10 mM Tris–MOPS (pH 7.4), 1 mM
KH2PO4, and 10 µM EGTA, supplemented with 2 µM
rotenone. Mitochondria (1 mg) were energized with
5 mM succinate after 2 min of Ca2+ addition (60 nmol).
Statistical Analysis
The results are presented as mean ± SEM for the
number of experiments indicated in the legends to the
figures. Multiple comparisons were performed using
one-way ANOVAs.
RESULTS
The respiratory control ratio (RCR) is a measure
of the dependence of the respiratory rate on oxidative
phosphorylation. A decrease of the RCR ratio gener-
ally indicates that the structural integrity of mitochon-
dria has been affected. On the other hand, the ADP/O
ratio is a measure of the efficiency of mitochondrial
oxidative phosphorylation. RCR and ADP/O ratios
of liver mitochondria isolated from either male or fe-
malenimesulide-treated rats arenotdifferent relative to
the controls (Table 1), which indicates that nimesulide
treatment neither affects the mitochondrial respiration
nor does it impair the efficiency of ATP synthesis (as
indicated by the ADP/O ratio) of isolated liver mito-
chondria. The values of the RCR are around 6, denot-
ing a good mitochondrial preparation, which is further
confirmed by the proximity to 2 of the ADP/O values.
To obtain further insight into the effects of nime-
sulide on the capacity of mitochondria to use energy
arising from oxidative metabolism,  fluctuations
TABLE 1. Effect of Nimesulide on RCR and ADP/O Ra-
tios of Rat Liver Mitochondria Isolated From Control and
Nimesulide-Treated Ratsa
RCR ADP/O
Control (male) 6.00 ± 0.04 1.91 ± 0.02
Nimesulide (male) 5.99 ± 0.04 1.89 ± 0.01
Control (female) 5.96 ± 0.04 1.90 ± 0.02
Nimesulide (female) 5.97 ± 0.04 1.89 ± 0.01
aData aremeans± SEMobtained from three differentmitochondrial prepara-
tions for each experimental group. For each mitochondrial preparation, assays
were performed in triplicate.
TABLE 2. Effect of Nimesulide Treatment on Mitochondrial
Transmembrane Potential () Fluctuationsa
 (−mV)
Succinate ADP
Energization Depolarization Repolarization Lag Phase (s)
Control 229 ± 0.6 31.0 ± 0.83 30.8 ± 0.8 61 ± 2.2
(male)
Nimesulide 227 ± 1.0 29.6 ± 0.8 29.5 ± 0.9 62.5 ± 2.1
(male)
Control 228 ± 0.6 28.8 ± 0.5 27.3 ± 0.4 57.8 ± 1.3
(female)
Nimesulide 228 ± 0.5 29.8 ± 0.8 28.3 ± 0.6 58.6 ± 1.2
(female)
aTable shows the average response of membrane potential developed with
succinate, thedecrease inmembranepotential afterADPaddition, the lagphase
that precedes repolarization, and the repolarization value after ADP phospho-
rylation. There are no statistically significant differences when compared to
controls. Data are mean ± SEM obtained from three different mitochondrial
preparations (with assays in quadruplicate for each preparation).
associated with mitochondrial respiration and the
phosphorylation cycle induced by ADP were also in-
vestigated. Mitochondria isolated from control and
nimesulide-treated animals (male or female) show no
difference relatively to  fluctuations (Table 2). Upon
energizationwith succinate, all groups ofmitochondria
(isolated from control and treated animals) developed
the same  (around −230 mV). The depolarization
that follows the addition of ADP, the repolarization
rate, and the recovery of  after the phosphorylation
cycle are also not affected after nimesulide treatment.
Finally, the lag phase that precedes the repolarization
of the mitochondrial membrane is not affected by the
treatment with nimesulide. As the lag phase represents
the time required for the phosphorylation of added
ADP, nimesulide does not affect the time required
for the phosphorylation of ADP (which is in accor-
dance with the unchanged ADP/O values). After the
phosphorylation cycle, the nucleotide contents (ATP,
ADP, and AMP) were also analyzed by HPLC. The en-
ergetic charge of mitochondria isolated from control
rats and nimesulide-treated rats are similar (data not
shown). This result confirms that nimesulide does not
alter the phosphorylation efficiency of mitochondria,
as described previously.
The nitroreductive metabolism of nimesulide in-
volves redox cycling. The resulting production of
reactive oxygen species (namely superoxide anion
molecules) can potentially lead to intracellular oxida-
tive stress and result in mitochondrial dysfunction
through the opening of the MTP pore. Following this
idea, the possible in vivo effects of nimesulide on
the opening of the mitochondrial permeability tran-
sition pore was also investigated. Figure 1 represents
a typical recording from swelling experiments car-
ried out in mitochondria from male Wistar rats. The
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FIGURE1. Effect of nimesulide treatment on calcium-dependent in-
duction of the MPT. Rat liver mitochondria (1 mg) were incubated at
25◦C in 2mLof sucrose 200mM,Tris–MOPS 10mM(pH7.2), KH2PO4
1 mM, and EGTA 10 µM, supplemented with 2 µM rotenone. Mito-
chondria were energized with 5 mM succinate before adding CaCl2.
Light scatteringwasmonitored continuously at 540nm,which served
as the basis for assessing changes in mitochondrial volume. Shown
here is the result of experiments involving male rats. Results ob-
tained with female rats do not differ (data not shown). The traces
are typical of three different preparations, with assays done in du-
plicate. (A) Mitochondria isolated from vehicle (DMSO)-treated rats
(control) and (B) mitochondria isolated from nimesulide-treated rats.
CsA: Cyclosporin A.
MTP pore was induced by the addition of calcium
(60nmol) to succinate-energizedmitochondria.As seen
in Figure 1B, mitochondria isolated from nimesulide-
treated rats show a susceptibility to the opening of the
MPT pore comparable to those isolated from control
rats (Figure 1A). Results obtainedwith female ratswere
identical (data not shown). Cyclosporin A, the specific
inhibitor of the MPT pore [30], completely inhibited
swelling in all experimental groups (Figure 1 and data
not shown).
 collapse and calcium efflux associated with
MPT pore opening were also studied in both control
and nimesulide-treated rats. The results presented in
Figure 2 illustrate the fluctuations ofmitochondrial
associated with the addition of two successive pulses
of 30 nmol of calcium to succinate-energizedmitochon-
dria from male rats. Adding 30 nmol of calcium to en-
ergized mitochondria (of control and treated animals)
caused a transient depolarization of the membrane po-
tential (Figures 2A and 2B). The membrane returned
to near the original potential within less than 1 min.
However, after a second pulse of 30 nmol calcium, the
mitochondria were unable to sustainmembrane poten-
tial and underwent depolarization. The  collapse is
completely prevented by cyclosporinA (in both control
and treated rats; Figure 2C),which indicates that thede-
polarization is related to the induction of theMPTpore.
Results obtainedwith female rats are very similar (data
not shown). Again, no differences were found among
experimental groups.
FIGURE 2. Effect of nimesulide treatment on mitochondrial 
associated with Ca2+-induced depolarization of succinate-energized
mitochondria. Freshly isolated rat liver mitochondria (1 mg) were
incubated at 25◦C in 1 mL of sucrose 200 mM, Tris–MOPS 10 mM
(pH 7.2), KH2PO4 1 mM, EGTA 10 µM supplemented with 2 µM
rotenone.  was recorded continuously using a TPP+-selective
electrode linked to a suitable recorder. Energization was initiated
by adding 5 mM succinate followed by two pulses of 30 nmol CaCl2.
The second pulse of calcium induced the MPT (A and B). Note that
cyclosporin A (CsA) prevented the depolarization induced by Ca2+
in both experimental groups (C [recordings from both groups were
superimposed]). Shown here is the result of experiments involv-
ing male rats. Results obtained with female rats do not differ (data
not shown). The traces are typical of three different preparations,
with assays done in duplicate. (A) Mitochondria isolated from ve-
hicle (DMSO)-treated rats (control), (B) mitochondria isolated from
nimesulide-treated rats, and (C) mitochondria isolated from male
nontreated animals or treated animals in the presence of 1 µM of
cyclosporin A.
The lack of effect of nimesulide in the induction
of mitochondrial permeability transition is further ev-
idenced by following calcium fluxes through the mi-
tochondrial membrane. Energized mitochondria accu-
mulate calcium from themedium for a certain period of
time. The rapid uptake of calcium following energiza-
tion with succinate was followed by a dynamic steady
state corresponding to the equilibrium between the in-
flux and the efflux of calcium. The results reported in
Figure 3 show that mitochondria isolated from male
nimesulide-treated rats (Figure 3B) and male control
animals (Figure 3A) accumulated approximately the
same amount of calcium, and released the preaccumu-
lated calcium due to the induction of the MPT after the
same lag time. Cyclosporin A was able to prevent cal-
cium release to the external buffer in both experimental
groups (Figure 3C). As with previous data, results ob-
tained with female animals were duplications of the
results obtained with male animals (data not shown).
Finally, we also followed variations of mitochon-
drial oxygen consumption upon calcium additions.
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FIGURE3. Effect of nimesulide treatment onmitochondrial Ca2+ re-
lease associated with permeability transition pore opening. Freshly
isolated rat liver mitochondria (1 mg) were incubated at 25◦C in
1 mL of sucrose 200 mM, Tris–MOPS 10 mM (pH 7.2), KH2PO4
1 mM, and EGTA 10 µM supplemented with 2 µM rotenone. En-
ergization was initiated by adding 5 mM succinate after the addition
of 60 nmol of CaCl2. The uptake of Ca2+ and release of sequestered
Ca2+ by mitochondria were continuously recorded using a Ca2+-
selective electrode linked to a suitable recorder. Note that cyclosporin
A prevented the release of Ca2+ (C), which confirms the involvement
of the mitochondrial permeability transition in this phenomenon.
(A) Mitochondria isolated from vehicle (DMSO)-treated rats (con-
trol), (B) mitochondria isolated from nimesulide-treated rats, and
(C) mitochondria isolated from male nontreated or treated animals
in the presence of 1µM of cyclosporin A (CsA [recordings from both
groupswere superimposed]). Shownhere is the result of experiments
involving male rats. Results obtained with female rats were similar
(data not shown). The traces are typical of three different prepara-
tions, with assays done in duplicate.
There was no difference between experimental groups
regarding calcium-induced mitochondrial stimulation
of respiration (data not shown). Cyclosporin A again
prevented uncoupling of respiration due to calcium-
induced MPT (data not shown).
DISCUSSION
Nimesulide is a well-tolerated nonsteroidal anti-
inflammatory drug (NSAID) with a wide range of
clinical uses. However, its use has raised some con-
cern regarding its potential hepatotoxicity in suscep-
tible patients [31]. The exact biochemical mechanisms
of nimesulide toxicity have not been fully elucidated,
yet some studies have suggested an important role
for nimesulide-induced mitochondrial dysfunction in
the pathogenesis of liver injury. In fact, in vitro stud-
ies have demonstrated that nimesulide acts as a po-
tent protonophoretic uncoupler andNAD(P)H oxidant
in isolated rat liver mitochondria [18], and in iso-
lated rat hepatocytes [20]. These authors also demon-
strated that nimesulide promotes mitochondrial Ca2+
efflux through the mitochondrial permeability transi-
tion (MPT) pore within a concentration range claimed
by the authors to be potentially reached in vivo (ap-
proximately 5 µM). The peak plasma concentrations
of nimesulide in humans are indeed in the range
10–20 µM [24], but considering that the drug is 99%
bound to plasma protein, the unbound, bioavail-
able fraction is significantly lower. Nevertheless, these
observations raised the possibility that nimesulide,
through its capability to interfere with mitochondrial
bioenergetics, has the ability to interfere with the en-
ergy production and Ca2+ homeostasis in the liver cell,
which in turn may constitute a relevant mechanism for
the reported nimesulide-induced liver toxicity. Later,
Tay et al. [24] described that mitochondrial uncoupling
induced by nimesulide is actually the trigger for induc-
tion of the MPT, which further leads to the generation
of oxidative stress on isolated liver mitochondria.
The rat is generally regarded as a suitablemodel for
NSAIDs damage in humans [32,33] In this study, we in-
vestigated whether mitochondria isolated from the liv-
ers of rats treatedwith supratherapeutic doses of nime-
sulide (50 mg/kg, twice daily, for 5 days) showed early
signs of dysfunction, including a decreased calcium-
loading capacity, which has been shown to be a reliable
marker for drug-induced mitochondrial toxicity [34].
In addition, we tried to demonstrate whether previous
conclusions taken from in vitro studies ofmitochondria
can be extrapolated to in vivo situations.
Pharmacokinetic studies with 100 mg nimesulide
administrated twice daily for 5 days in humans re-
vealed that the drug is rapidly distributed, extensively
bound to albumin, and eliminated with a terminal
half-life of about 4 h [25]. Nimesulide is oxidatively
metabolized via liver cytochrome P450 mainly to the
4-hydroxy-metabolite (4-OH-NME), which has simi-
lar pharmacological properties to the parent drug, al-
though with a lower potency. The period that elapses
before the appearance of the metabolite in the circula-
tion is short (approximately 1 h) and half-life (t1/2) is
between 3.2 and 8 h. The plasma elimination is progres-
sive, with a t1/2 in plasma of 2–5 h for the parent drug
and 3–9 h for 4-OH-NME, thus allowing for conve-
nient 100-mg twice-daily dosage without any evidence
of accumulation [35]. The elimination of nimesulide is
not influenced by age or gender, but its use is con-
traindicated in patients with hepatic impairment [36].
The usual therapeutic regimen is 100 mg twice daily,
with discontinuation of the administration after 5 days.
The pharmacokinetic profiles of nimesulide in humans
and rats appear to be similar [25,37,38].
Data from the present investigation demonstrate
that the RCR and the phosphorylation index (ADP/O)
of liver mitochondria isolated from nimesulide-treated
J Biochem Molecular Toxicology DOI 10:1002/jbt
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rats were not affected, which means that the structural
integrity and the phosphorylation capability of mito-
chondria were maintained (Table 1). These results indi-
cate that mitochondrial bioenergetic function was not
impaired by nimesulide.
To further confirm that nimesulide treatment did
not impair hepatic mitochondria, the transmembrane
electric potential (Table 2) associated with mitochon-
drial respiration and the phosphorylation cycle in-
duced by ADP was also measured. The study of  is
essential for an integrated appraisal of the mitochon-
drial function, since it reflects basic useful energetic
relationships. Nimesulide treatment affected neither
the energization by succinate nor the  fluctuations
linked to the phosphorylation cycle, confirming that
the drug treatment did not interfere with the respi-
ratory chain or with the phosphorylation system of
mitochondria, irrespective of whether they had been
isolated from male or female animals.
Mitochondrial dysfunction can also be triggered by
stress-induced opening of the MPT pore. Induction of
the MPT is implicated in the mechanisms of cell injury
caused by a number of xenobiotics, many of which be-
have as oxidants [39,40]. In fact, the opening of theMPT
pore upon increased oxidative stress is well character-
ized. It is now well recognized that the MPT is closely
involved in cell death either by necrosis or by apoptosis
[22,23,39,41]. In this regard, there is evidence that nime-
sulide can induce intracellular oxidative stress in vitro;
its capability for redox cycling can produce superox-
ide anion and pose an oxidative stress [24,31,42]. Tay
et al. [24] demonstrated that the oxidative stress of iso-
lated liver mitochondria exposed to nimesulide was a
consequence of MPT pore opening.
In vivo effects of nimesulide on mitochondrial cal-
cium handling have not been analyzed so far. Bearing
this in mind, we investigated the effect of nimesulide
treatment upon calcium-dependentmitochondrial per-
meability transition. A hallmark of theMPT is the high-
amplitude swelling induced by calcium in the presence
of phosphate. In our assays, the addition of calcium to
energized mitochondria caused a large-amplitude de-
crease in light scattering, typical of the mitochondrial
swelling induced by the opening of the MPT pore in
liver mitochondria. The inhibition by Cyclosporin A
is evidence for the induction of the MPT, which is at-
tributed to the Ca/Pi-induced stimulation of hydrogen
peroxide generation [43]. The fact that the curve pro-
file for mitochondria isolated from control and treated
animals (of both genders) is the same (Figure 1) indi-
cates that the susceptibility for the induction of MPT is
unaltered.
Confirming the previous results, we also verified
that mitochondria isolated from either nimesulide-
treated (of both sexes) or nontreated animals show the
same profile of  fluctuations, indicating again that
the susceptibility for the calcium-inducedMPTwas not
altered (Figure 2). The final evidence arises from de-
termination of extramitochondrial calciummovements
using a Ca2+-selective electrode. Again, results confirm
thepreviousdata (Figure 3). Indeed, livermitochondria
isolated from nimesulide-treated and control animals
were able to accumulate the same amount of calcium
and to retain the calcium for the same length of time
before its release to the reaction medium. The result
indicates that nimesulide did not confer any particular
susceptibility to the induction of MPT. Cyclosporin A
was able to inhibit calcium release, further confirming
MPT pore opening induced by excess of calcium in the
presence of phosphate, as depicted for male rats in the
curves of Figure 3.
The role of the MPT in drug-induced organ dys-
function iswell documented. However, nimesulide did
not promote any early alterations inmitochondrial sus-
ceptibility to MPT induction. The result is also in ac-
cordance with the observation that the phosphoryla-
tion capability of mitochondria isolated from treated
animals was not affected. On the basis of in vitro ex-
periments, several investigators have suggested that
mitochondrial dysfunctionmay be involved in the hep-
atotoxicity induced by nimesulide. Unfortunately, only
one of these in vitro studies was performed in the pres-
ence of physiological levels of plasma albumin. This is
a key factor because nimesulide is 99% bound to albu-
min, and only a very small free drug fraction can enter
cells and mitochondria. This aspect is intrinsically con-
sidered in the present in vivo study. Berson et al. [44]
observed that nimesulide uncouples mitochondria and
triggers theMPT in isolatedmitochondria or hepatoma
cells incubated in the absence of albumin. However, in
the presence of physiological amounts of albumin, such
toxic effects were not observed.
To obviate for the presumably low free drug levels
following clinical administration of nimesulide, an ex-
perimental protocol using a supratherapeutic dose of
the drug was chosen. In spite of these extreme condi-
tions, present data clearly show that nimesulide failed
to induce early adverse effects on mitochondria. It is
also noteworthy that there is no gender-related predis-
position to the potential toxic effects of nimesulide on
mitochondrial bioenergetics.
In sequence of the results obtained, we performed
additional experiments in three extramale rats exposed
for longer times to the drug (animals were treated for
28 days with 50 mg/kg nimesulide twice daily). The
same mitochondrial parameters described in the study
were evaluated as rats were killed 2 h after the last
injection. Under these conditions, mitochondria strik-
ingly remained without any noticeable bioenergetic
alteration (data not shown).
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The 5-day protocol represents an approach in
agreement with the usual therapeutic regimen in hu-
mans, that is, 5 days with 100 mg twice daily and dis-
continuation after. In our protocol, we have followed
a washout period of 2 days to confirm whether nime-
sulide had persistent effects on mitochondria, which
was already described with other well-known drugs
(e.g., doxorubicin) [34,45].
Another important clue for the lack of effect of
in vivo nimesulide treatment on hepatic mitochondrial
function derives from the results obtained by Mingatto
et al. [18], who clearly demonstrated that one of the
nimesulide metabolites (the product of reduction of
the nitro group to an amine derivative) does not have
the same effects of the parent compound regarding
the induction of the permeability transition on isolated
mitochondrial fractions.
In conclusion, nimesulide had no early effects
on liver mitochondrial function following repeated
administration of a largely supratherapeutic dose
(50 mg/kg, twice daily for five consecutive days) to
rats. This is in contrast to the positive results obtained
in vitro by various authors and may be at least in
part due to the absence of physiological levels of al-
bumin in these in vitro experiments and to the hepatic
metabolism of nimesulide whereby the drug is con-
verted to less toxic metabolites.
The hypothesis put forward by various investi-
gators that early mitochondrial dysfunction may be
linked to very rare clinical cases of nimesulide-induced
hepatotoxicity was not confirmed in this study, as hep-
atic mitochondria from nimesulide-treated rats had
their performance unaltered. Our results also empha-
size that in vitro studies cannot be easily extrapolated
to in vivo systems.
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